TRAJENTA®: Favourable safety and tolerability for a broad range of patients.

TRAJENTA® has demonstrated a favourable safety and tolerability profile, with an incidence of adverse events similar to placebo.1

Please see the Summary of Product Characteristics for more information.

TRAJENTA® one dose, once daily
With one dose, once daily, TRAJENTA® can be prescribed regardless of disease duration, ethnicity, body mass index (BMI), liver and kidney function.1
Independent of:1
TRAJENTA® can be prescribed regardless of renal function
TRAJENTA® can be prescribed regardless of liver function
TRAJENTA® can be prescribed regardless of background T2D therapy
TRAJENTA® can be prescribed regardless of age
TRAJENTA® can be prescribed regardless of ethnicity
TRAJENTA® can be prescribed regardless of body mass index (BMI)

 

Want to understand more about the safety of TRAJENTA®?